Reconstitution of hematopoiesis following intrauterine transplantation of stem cells.

Children's Institute for Surgical Science, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Methods in molecular medicine 02/2005; 105:81-94.
Source: PubMed


In utero hematopoietic stem cell transplantation is an entirely nonmyeloablative approach to achieve mixed hematopoietic chimerism and associated donor-specific tolerance. This chapter provides the rationale and methodologic detail for the administration of stem cells to the "preimmune" mouse fetus by a variety of routes. The development of murine model systems for in utero transplantation has accelerated progress in the field of in utero hematopoietic stem cell transplantation. Creative use of these models should also have experimental application to the fields of fetal gene therapy, stem cell biology, and developmental biology.

5 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It is important to recognize that it is only during our lifetime, the last decades of the 20th century, that the fetus has become a patient, with much of the credit due to the powerful imaging and sampling techniques now available. The secret life of the fetus has been revealed and with it the details of normal fetal growth and development and the opportunity to identify, detect, and treat fetal anomalies surgically. From a nursing perspective, this article provides a historical overview of fetal treatment, including the development and evolution of fetal surgery, a description of some milestones of this multifaceted, complex area, a delineation of the components and dynamics of collaborative team management of fetal therapy patients, and finally an introduction to introduce emerging trends that will affect the future of this rapidly evolving field.
    The Journal of perinatal & neonatal nursing 01/2007; 21(1):11-9; quiz 20-1. · 1.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A number of properties and therapeutic applications of fetal cells/tissues have been explored to date, with variable results. A little over a decade ago, a novel concept in perinatal surgery was introduced, involving the harvest of fetal cells, which are then processed to engineer tissue in parallel with the remainder of gestation, so that an infant or fetus with a prenatally diagnosed birth defect can benefit from having autologous, expanded tissue readily available for surgical implantation in the perinatal period. More recently, fetal annexes such as the amniotic fluid, placenta, and umbilical cord have been shown to provide minimally invasive access to unique fetal progenitor cell populations conducive to tissue engineering. Despite promising results in large animal models, controlled clinical trials involving fetal tissue engineering have yet to be reported. At the same time, it has been shown experimentally that many of the complications of tissue engineering can be better managed, if not totally prevented, when fetal cells are used. Compared with mature cells, fetal cells typically proliferate more rapidly, are more plastic in their differentiation potential, frequently produce more angiogenic and trophic factors, tend to be less immunogenic, can survive at lower oxygen tensions, commonly lack strong intercellular adhesions, and display better survival after refrigeration and cryopreservation protocols. By the same token, the developmental and long term impacts of tissue implantations into a fetus or neonate are unmatched by most other age groups. This chapter offers an overview of tissue engineering as it relates to the fetus, along with general perspectives on fetal cell and tissue transplantation.
    Principles of Tissue Engineering, 01/2007: pages 377-387; , ISBN: 978-0-12-370615-7
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The competence of the immune system of the developing fetus to act as a barrier to in utero hematopoietic-cell transplantation (IUHCT) has been a source of debate. Until now, comparisons of allogeneic and congenic engraftment have been inconclusive due to methodologic limitations resulting in minimal and inefficient engraftment. In this study, E14 fetal mice received transplants of either allogeneic or congenic bone marrow using a new intravascular technique that allows definitive administration of much higher doses of donor cells. Our results demonstrate that 100% of surviving recipients demonstrate engraftment at 1 week of age, but that 70% of allogeneic recipients lose engraftment by 1 month of age, and 80% ultimately fail to sustain long-term chimerism. In contrast, all congenic recipients maintain stable, long-term, multilineage chimerism. These results strongly support an immune barrier to allogeneic engraftment after IUHCT.
    Blood 03/2007; 109(3):1331-3. DOI:10.1182/blood-2006-04-018606 · 10.45 Impact Factor
Show more

Similar Publications